Reported Earnings • May 05
Full year 2026 earnings released: EPS: ₹3.70 (vs ₹0.03 in FY 2025) Full year 2026 results: EPS: ₹3.70 (up from ₹0.03 in FY 2025). Revenue: ₹165.1m (down 32% from FY 2025). Net income: ₹6.38m (up ₹6.33m from FY 2025). Profit margin: 3.9% (up from 0% in FY 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. New Risk • Mar 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹828m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹828m free cash flow). Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹758.3m market cap, or US$8.08m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m). New Risk • Mar 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 420% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (420% increase in shares outstanding). Market cap is less than US$10m (₹722.2m market cap, or US$7.72m). Minor Risk Revenue is less than US$5m (₹155m revenue, or US$1.7m). Ankündigung • Feb 10
Sarda Proteins Ltd to Report Q3, 2026 Results on Feb 14, 2026 Sarda Proteins Ltd announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026 Board Change • Jan 12
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). MD & Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Ankündigung • Nov 05
Sarda Proteins Ltd to Report Q2, 2026 Results on Nov 14, 2025 Sarda Proteins Ltd announced that they will report Q2, 2026 results on Nov 14, 2025 Ankündigung • Aug 12
Sarda Proteins Ltd to Report Q1, 2026 Results on Aug 14, 2025 Sarda Proteins Ltd announced that they will report Q1, 2026 results on Aug 14, 2025 Board Change • Aug 11
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jul 14
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jun 23
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jun 02
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • May 19
Full year 2025 earnings released: EPS: ₹0.03 (vs ₹0.11 in FY 2024) Full year 2025 results: EPS: ₹0.03 (down from ₹0.11 in FY 2024). Revenue: ₹241.9m (up ₹229.0m from FY 2024). Net income: ₹51.0k (down 74% from FY 2024). Profit margin: 0% (down from 1.5% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 156 percentage points per year, which is a significant difference in performance. Ankündigung • May 13
Sarda Proteins Ltd to Report Q4, 2025 Results on May 15, 2025 Sarda Proteins Ltd announced that they will report Q4, 2025 results on May 15, 2025 New Risk • Mar 20
New major risk - Revenue and earnings growth Earnings have declined by 5.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 5.2% per year over the past 5 years. Market cap is less than US$10m (₹215.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹241m revenue, or US$2.8m). Board Change • Mar 03
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Additional Executive Director Chirag Thumar is the most experienced director on the board, commencing their role in 2024. Additional Independent Director Dhairyakumar Thakkar was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Ankündigung • Jan 13
Sarda Proteins Ltd to Report Q3, 2025 Results on Jan 17, 2025 Sarda Proteins Ltd announced that they will report Q3, 2025 results on Jan 17, 2025 Ankündigung • Oct 26
Sarda Proteins Ltd to Report Q2, 2025 Results on Nov 08, 2024 Sarda Proteins Ltd announced that they will report Q2, 2025 results on Nov 08, 2024 Ankündigung • Sep 11
Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024 Sarda Proteins Ltd, Annual General Meeting, Sep 28, 2024, at 16:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2025 earnings released: ₹0.46 loss per share (vs ₹0.01 loss in 1Q 2024) First quarter 2025 results: ₹0.46 loss per share (further deteriorated from ₹0.01 loss in 1Q 2024). Net loss: ₹801.0k (loss widened ₹776.0k from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Ankündigung • Jul 15
Sarda Proteins Ltd Announces Resignation of Shipra Gandhi as Chief Financial Officer Sarda Proteins Ltd. has received resignation letter dated 15t July, 2024 from Mrs. Shipra Gandhi, Chief Financial Officer (CFO) of the company informing about her resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from the closure of business hours of 15th July, 2024. Ankündigung • Jun 25
Sarda Proteins Ltd Appoints Khilan Hareshbhai Savaliya as Additional Director (Non-Executive) Sarda Proteins Ltd. at its board of directors meeting held on June 24, 2024, approved appointment of Mr. Khilan Hareshbhai Savaliya (DIN: 08790209) as the Additional Director (Non-Executive)' of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, with effect from 24th day of June, 2024. Terms of Appointment: To hold office till the ensuing Annual General Meetingof the company. With an experience of 3+ years in the field of Turnkey Project Management, Mr. Khilan Hareshbhai Savaliya brings a wealth of knowledge and productivity to the organization. Board Change • Jun 05
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Mahavir Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • May 31
Sarda Proteins Ltd Appoints Chirag Shantilal Thumar as Additional Executive Director Sarda Proteins Ltd. Board of Directors of the Company in meeting held on 28 day of May, 2024, approved the appointment of Mr. Chirag Shantilal Thumar as the Additional Director (Executive) of the Company on the recommendation of Nomination and Remuneration Committee in pursuance to Section 161 of the Companies Act, 2013, effective 28th May, 2024. Recent Insider Transactions • May 28
MD & Director recently sold ₹3.0m worth of stock On the 24th of May, Deepak Data sold around 35k shares on-market at roughly ₹84.58 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Deepak's only on-market trade for the last 12 months. Reported Earnings • May 02
Full year 2024 earnings released: EPS: ₹0.11 (vs ₹0.19 loss in FY 2023) Full year 2024 results: EPS: ₹0.11 (up from ₹0.19 loss in FY 2023). Revenue: ₹14.6m (down 75% from FY 2023). Net income: ₹194.0k (up ₹524.3k from FY 2023). Profit margin: 1.3% (up from net loss in FY 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Apr 22
Sarda Proteins Ltd to Report Q4, 2024 Results on Apr 30, 2024 Sarda Proteins Ltd announced that they will report Q4, 2024 results on Apr 30, 2024 Board Change • Feb 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹0.04 (vs ₹0.01 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.04 (up from ₹0.01 in 3Q 2023). Revenue: ₹10.4m (down 54% from 3Q 2023). Net income: ₹69.0k (up 306% from 3Q 2023). Profit margin: 0.7% (up from 0.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 06
Sarda Proteins Ltd to Report Q3, 2024 Results on Feb 13, 2024 Sarda Proteins Ltd announced that they will report Q3, 2024 results on Feb 13, 2024 Ankündigung • Nov 10
Sarda Proteins Ltd Announces Resignation of Somya Data as Chief Financial Officer Sarda Proteins Ltd. announced that it has received Resignation letter dated 08t November, 2023. from. Mr. Somya Data, Chief Financial Officer (CFO) of the Company informing about his resignation from the post of Chief Financial Officer (CFO) due to some personal and unavoidable reason with effect from closure of business hours of November 30, 2023. Reported Earnings • Nov 09
Second quarter 2024 earnings released: ₹0.03 loss per share (vs ₹0.02 profit in 2Q 2023) Second quarter 2024 results: ₹0.03 loss per share (down from ₹0.02 profit in 2Q 2023). Revenue: ₹413.0k (down 99% from 2Q 2023). Net loss: ₹51.0k (down 289% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Oct 31
Sarda Proteins Ltd to Report Q2, 2024 Results on Nov 07, 2023 Sarda Proteins Ltd announced that they will report Q2, 2024 results on Nov 07, 2023 Ankündigung • Aug 16
Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023 Sarda Proteins Ltd, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time. Ankündigung • Aug 08
Sarda Proteins Ltd to Report Q1, 2024 Results on Aug 14, 2023 Sarda Proteins Ltd announced that they will report Q1, 2024 results on Aug 14, 2023 New Risk • Jun 30
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹58m revenue, or US$706k). Market cap is less than US$10m (₹79.4m market cap, or US$967.3k). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • Jun 04
Full year 2023 earnings released: ₹0.19 loss per share (vs ₹1.78 profit in FY 2022) Full year 2023 results: ₹0.19 loss per share (down from ₹1.78 profit in FY 2022). Revenue: ₹59.6m (down 45% from FY 2022). Net loss: ₹331.0k (down 111% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 24
Sarda Proteins Ltd to Report Q4, 2023 Results on May 30, 2023 Sarda Proteins Ltd announced that they will report Q4, 2023 results on May 30, 2023 Valuation Update With 7 Day Price Move • May 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹55.35, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 91% over the past year. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹49.69, the stock trades at a trailing P/E ratio of 28.8x. Average trailing P/E is 30x in the Consumer Retailing industry in India. Total returns to shareholders of 51% over the past year. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Mahavir Sharma was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹56.55, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 418% over the past three years. Reported Earnings • Feb 01
Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.32 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.01 (down from ₹0.32 in 3Q 2022). Revenue: ₹22.7m (down 17% from 3Q 2022). Net income: ₹17.0k (down 97% from 3Q 2022). Profit margin: 0.1% (down from 2.0% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jan 31
Sarda Proteins Ltd Announces Chief Financial Officer Changes Board of Directors of the Sarda Proteins Ltd, at its meeting held on, 30th January, 2023 has appointed Mr. Somya Data as the Chief Financial Officer (CFO) of the Company with effect from 01st February, 2023. Reason for Change: Due to resignation tendered by Mr. Himanshu Gupta, the Board has decided to appoint Mr. Somya Data as the Chief Financial Officer (CFO) of the company. Date of Appointment: With effect from 01st February, 2023 Qualification and Professional Experience: He is a graduate in Commerce from University of Rajasthan and is also CMA-Inter qualified from the Institute of Cost Accountants of India. He hasimmense knowledge of Financial Planning, Management of Financial Risks, Book Keeping, Financial Reporting, Indian Accounting Standards and Cost Accounting Standards. Ankündigung • Jan 24
Sarda Proteins Ltd to Report Q3, 2023 Results on Jan 30, 2023 Sarda Proteins Ltd announced that they will report Q3, 2023 results on Jan 30, 2023 Ankündigung • Jan 20
Sarda Proteins Ltd Announces Resignation of Himanshu Gupta as Chief Financial Officer, Effective 30 January 2023 Sarda Proteins Ltd. announced that the company has received resignation letter dated 19 January 2023 from Mr. Himanshu Gupta, chief financial officer (CFO) of the company informing about his resignation from the post of chief financial officer (CFO) due to some personal reasons with effect from closure of business hours of 30 January 2023. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₹60.35, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 31x in the Consumer Retailing industry in India. Total returns to shareholders of 453% over the past three years. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹90.90, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 41x in the Consumer Retailing industry in India. Total returns to shareholders of 732% over the past three years. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₹123, the stock trades at a trailing P/E ratio of 60.4x. Average trailing P/E is 45x in the Consumer Retailing industry in India. Total returns to shareholders of 1,029% over the past three years. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment deteriorated over the past week After last week's 23% share price decline to ₹163, the stock trades at a trailing P/E ratio of 79.8x. Average trailing P/E is 37x in the Consumer Retailing industry in India. Total returns to shareholders of 1,390% over the past three years. Reported Earnings • Oct 21
Second quarter 2023 earnings released: EPS: ₹0.02 (vs ₹0.14 loss in 2Q 2022) Second quarter 2023 results: EPS: ₹0.02 (up from ₹0.14 loss in 2Q 2022). Revenue: ₹27.9m (up 274% from 2Q 2022). Net income: ₹27.0k (up ₹266.0k from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has increased by 161% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Oct 13
Sarda Proteins Ltd to Report Q2, 2023 Results on Oct 19, 2022 Sarda Proteins Ltd announced that they will report Q2, 2023 results on Oct 19, 2022 Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improved over the past week After last week's 15% share price gain to ₹41.30, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 32x in the Consumer Retailing industry in India. Total returns to shareholders of 297% over the past three years. Ankündigung • Aug 06
Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022 Sarda Proteins Limited, Annual General Meeting, Sep 23, 2022, at 12:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 17% share price gain to ₹32.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 27x in the Consumer Retailing industry in India. Total returns to shareholders of 213% over the past three years. Ankündigung • Jul 29
Sarda Proteins Limited to Report Q1, 2023 Results on Aug 05, 2022 Sarda Proteins Limited announced that they will report Q1, 2023 results on Aug 05, 2022 Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improved over the past week After last week's 18% share price gain to ₹27.50, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 22x in the Consumer Retailing industry in India. Total returns to shareholders of 150% over the past three years. Ankündigung • May 19
Sarda Proteins Limited to Report Q4, 2022 Results on May 27, 2022 Sarda Proteins Limited announced that they will report Q4, 2022 results on May 27, 2022 Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.32 (up from ₹0.17 loss in 3Q 2021). Revenue: ₹27.4m (up 492% from 3Q 2021). Net income: ₹560.0k (up ₹854.0k from 3Q 2021). Profit margin: 2.0% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Board Change • Sep 17
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Non-Independent Director Vanita Bhanot is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Jun 27
Full year 2021 earnings released: ₹0.12 loss per share (vs ₹0.19 profit in FY 2020) The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2021 results: Revenue: ₹114.4m (up 112% from FY 2020). Net loss: ₹202.0k (down 161% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 21% share price gain to ₹17.87, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 276% over the past three years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 16% share price gain to ₹12.12, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 13x in the Consumer Retailing industry in India. Total returns to shareholders of 155% over the past three years. Reported Earnings • Feb 17
Third quarter 2021 earnings released: ₹0.17 loss per share (vs ₹0.56 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹4.63m (down 67% from 3Q 2020). Net loss: ₹294.0k (down 131% from profit in 3Q 2020). Ankündigung • Feb 04
Sarda Proteins Ltd. to Report Q3, 2021 Results on Feb 12, 2021 Sarda Proteins Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021 Valuation Update With 7 Day Price Move • Nov 06
Market bids up stock over the past week After last week's 16% share price gain to ₹10.00, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 23x. This compares to an average P/E of 19x in the Consumer Retailing industry in India. Total return to shareholders over the past year is a loss of 8.4%. Ankündigung • Nov 03
Sarda Proteins Ltd. to Report Q2, 2021 Results on Nov 09, 2020 Sarda Proteins Ltd. announced that they will report Q2, 2021 results on Nov 09, 2020 Ankündigung • Aug 25
Sarda Proteins Ltd. to Report Q2, 2020 Results on Sep 02, 2020 Sarda Proteins Ltd. announced that they will report Q2, 2020 results on Sep 02, 2020 